231 related articles for article (PubMed ID: 19950409)
1. Denosumab, osteoporosis, and prevention of fractures.
Kyrgidis A
N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950409
[No Abstract] [Full Text] [Related]
2. Denosumab, osteoporosis, and prevention of fractures.
Kiechl S; Willeit J; Schett G
N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
[No Abstract] [Full Text] [Related]
3. Denosumab, osteoporosis, and prevention of fractures.
Blackwood J
N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
[No Abstract] [Full Text] [Related]
4. Study shows that a new type of osteoporosis drug reduces fracture risk.
Harv Womens Health Watch; 2009 Oct; 17(2):6-7. PubMed ID: 19998553
[No Abstract] [Full Text] [Related]
5. Denosumab, osteoporosis, and prevention of fractures.
Blythe SL
N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
[No Abstract] [Full Text] [Related]
6. Denosumab (prolia) for postmenopausal osteoporosis.
Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
[No Abstract] [Full Text] [Related]
7. Denosumab in postmenopausal women with low bone mineral density.
Schwartzman J; Yazici Y
N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
[No Abstract] [Full Text] [Related]
8. Osteoporosis treatment options expand.
Mayo Clin Health Lett; 2010 Nov; 28(11):4. PubMed ID: 21158019
[No Abstract] [Full Text] [Related]
9. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
10. [Denosumab--a new efficient osteoporosis therapy].
Rejnmark L; Vestergaard P; Mosekilde L
Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
[TBL] [Abstract][Full Text] [Related]
11. Denosumab: new horizons in the treatment of osteoporosis.
Wilton JM
Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
[No Abstract] [Full Text] [Related]
12. [Innovations in the treatment of osteoporosis].
Tsourdi E; Hofbauer LC
Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
[No Abstract] [Full Text] [Related]
13. Denosumab in postmenopausal women with low bone mineral density.
Rifkin WD
N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
[No Abstract] [Full Text] [Related]
14. Drugs for postmenopausal osteoporosis.
Treat Guidel Med Lett; 2008 Oct; 6(74):67-74; quiz 75-6. PubMed ID: 18800025
[No Abstract] [Full Text] [Related]
15. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
17. [Osteoporosis].
Buck G; Perger L; Bischoff-Ferrari HA
Praxis (Bern 1994); 2011 Jul; 100(14):821-32. PubMed ID: 21732293
[No Abstract] [Full Text] [Related]
18. Preventing metastases to bone: denosumab or bisphosphonates?
Nanes MS
J Bone Miner Res; 2010 Mar; 25(3):437-9. PubMed ID: 20200989
[No Abstract] [Full Text] [Related]
19. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
[TBL] [Abstract][Full Text] [Related]
20. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
